Major tanshinones of Danshen (Salvia miltiorrhiza) exhibit different modes of inhibition on human CYP1A2, CYP2C9, CYP2E1 and CYP3A4 activities in vitro

被引:81
作者
Wang, Xin [1 ]
Cheung, Ching Mei [1 ]
Lee, Wayne Y. W. [1 ]
Or, Penelope M. Y. [1 ]
Yeung, John H. K. [1 ]
机构
[1] Chinese Univ Hong Kong, Fac Med, Sch Biomed Sci, Shatin, Hong Kong, Peoples R China
关键词
Danshen (Salvia miltiorrhiza); Tanshinones; CYP1A2; CYP2C9; CYP2E1; CYP3A4; Human liver microsomes; In vitro; HUMAN-LIVER-MICROSOMES; HERB-DRUG-INTERACTIONS; WARFARIN HYDROXYLATION; CATALYTIC-ACTIVITY; MOLECULAR-WEIGHT; CYTOCHROME-P450; PROBE; RATS; VIVO; ENZYME;
D O I
10.1016/j.phymed.2010.05.003
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
This study investigated the effects of tanshinones on human CYP1A2 (phenacetin O-deethylase), CYP2C9 (tolbutamide 4-hydroxylase), CYP2E1 (chlorzoxazone 6-hydroxylase) and CYP3A4 (testosterone 6 beta-hydroxylase) activities in vitro using pooled human liver microsomes and specific human CYP isoforms. Tanshinone I, tanshinone IIA, and cryptotanshinone were potent competitive CYP1A2 inhibitors (K-i = 1.5-2.5 mu M); medium competitive inhibitors of CYP2C9 (K-i = 22-62 mu M); medium competitive inhibitors of CYP2E1 (K-i = 3.67 mu M) for tanshinone land 10.8 mu M for crytotanshinone; but weak competitive inhibitors of CYP3A4 (K-i = 86-220 mu M) Dihydrotanshinone was a competitive inhibitor of human CYP1A2 (K-i = 0.53 mu M) and CYP2C9 (K-i = 1.92 mu M), a noncompetitive inhibitor of CYP3A4 (K-i = 2.11 mu M) but an uncompetitive CYP2E1 inhibitor. In conclusion, these results showed that tanshinones inhibited the metabolism of various CYP probe substrates in human liver microsomes and specific human CYP isoforms in vitro. Given that CYP1A2, 2C9, 2E1 and 3A4 are responsible for the metabolism and disposition of a large number of drugs currently used, the potential herb-drug interactions of Danshen preparations containing the major tanshinones with drugs which are substrates of these CYPs may be important. (C) 2010 Elsevier GmbH. All rights reserved.
引用
收藏
页码:868 / 875
页数:8
相关论文
共 42 条
[1]   Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine [J].
Carrillo, JA ;
Christensen, M ;
Ramos, SI ;
Alm, C ;
Dahl, ML ;
Benítez, J ;
Bertilsson, L .
THERAPEUTIC DRUG MONITORING, 2000, 22 (04) :409-417
[2]   THE EFFECTS OF DANSHEN (SALVIA-MILTIORRHIZA) ON WARFARIN PHARMACODYNAMICS AND PHARMACOKINETICS OF WARFARIN ENANTIOMERS IN RATS [J].
CHAN, K ;
LO, ACT ;
YEUNG, JHK ;
WOO, KS .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1995, 47 (05) :402-406
[3]   Interaction between warfarin and danshen (Salvia miltiorrhiza) [J].
Chan, TYK .
ANNALS OF PHARMACOTHERAPY, 2001, 35 (04) :501-504
[4]   Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes [J].
Eagling, VA ;
Tjia, JF ;
Back, DJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 45 (02) :107-114
[5]   Assessment of CYP1A2 activity in clinical practice: Why, how, and when? [J].
Faber, MS ;
Jetter, A ;
Fuhr, U .
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2005, 97 (03) :125-134
[6]   Determination of testosterone metabolites in human hepatocytes -: I.: Development of an on-line sample preparation liquid chromatography technique and mass spectroscopic detection of 6β-hydroxytestosterone [J].
Friedrich, G ;
Rose, T ;
Rissler, K .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2003, 784 (01) :49-61
[7]   ROLE OF HUMAN CYTOCHROME-P-450-IIE1 IN THE OXIDATION OF MANY LOW-MOLECULAR-WEIGHT CANCER SUSPECTS [J].
GUENGERICH, FP ;
KIM, DH ;
IWASAKI, M .
CHEMICAL RESEARCH IN TOXICOLOGY, 1991, 4 (02) :168-179
[8]   Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans [J].
Gurley, BJ ;
Gardner, SF ;
Hubbard, MA ;
Williams, DK ;
Gentry, WB ;
Cui, Y ;
Ang, CYW .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (03) :276-287
[9]  
Kalra Bhupinder Singh, 2007, Indian J Med Sci, V61, P102
[10]   Assessment of the hepatic and intestinal first-pass metabolism of midazolam in a CYP3A drug-drug interaction model rats [J].
Kanazu, T ;
Okamura, N ;
Yamaguchi, Y ;
Baba, T ;
Koike, M .
XENOBIOTICA, 2005, 35 (04) :305-317